Metagenomi Therapeutics, Inc. (MGX) intrinsic value & 10-year financials
Metagenomi Therapeutics, Inc. (MGX) has a Graham intrinsic value of $84.29 per share. At $0.78 on Oct 17, 2026, the stock trades 99% below that value. Over the last 4 fiscal years revenue shrank 24.9% a year to $25.2M, with an average return on invested capital of -344.9%.
- Graham intrinsic value
- $84.29
- Share price (Oct 17, 2026)
- $0.78
- Price vs Graham value
- 99% below
- Market cap
- $29.2M
- Revenue (FY2025)
- $25.2M
- Revenue growth (4-yr CAGR)
- -24.9%
- ROIC (10-yr avg)
- -344.9%
- Free cash flow (FY2025)
- -$89.5M
MGX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $25.2M | -$87.9M | -$2.36 | -$89.5M | -380.9% | -48.1% |
| FY2024 | $52.3M | -$78.1M | -$2.36 | -$112.2M | -170.0% | -1020.6% |
| FY2023 | $44.8M | -$68.3M | -$2.00 | -$101.2M | -175.4% | 33.9% |
| FY2022 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Metagenomi Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Metagenomi Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -8.1% ROIC.
Metagenomi Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Metagenomi Therapeutics, Inc. is modeled at -24.9% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $84.29 per share.